Cargando...

IL-2, the next best thing in chronic GVHD therapy?

In this issue of Blood, Koreth et al have reported that interleukin-2 (IL-2) is effective in chronic graft-versus-host disease (cGVHD) patients who had failed up to two prior lines of therapy.(1)

Guardado en:
Detalles Bibliográficos
Publicado en:Blood
Autores principales: Curtis, Lauren M., Pavletic, Steven Z.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2016
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4937357/
https://ncbi.nlm.nih.gov/pubmed/27389542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-05-711796
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!